BioCentury | Dec 22, 2020

Dec. 21-23 Regulatory Quick Takes: positive CHMP opinion for Pfizer-BioNTech COVID-19 vaccine; plus Urovant’s approval, a Feb. 9 adcomm for Keytruda in TNBC, NMPA reviewing a subcutaneous PD-L1, and more

...add-on therapy to other anti-epileptic therapies for patients two years of age and older. TARGETSADRB3 – Adrenergic receptor beta...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...Phase I testing for heart failure.TARGETSADRB3 – Adrenergic receptor beta...
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

...BPN14770 in Alzheimer’s disease, which is expected to read out this month. Targets ADRB3 - Adrenergic receptor beta...
BioCentury | Sep 6, 2019
Company News

Sumitomo Dainippon to bolster pipeline via deal for women's health, urology, rare disease vants for $3B

...Dainippon is expected to partner with two technology vants, Datavant and Alyvant. Targets: ADRB3 - Adrenergic receptor beta...
...Sciences GmbH J.P. Morgan Myovant Sciences GmbH Roivant Sciences GmbH Sumitomo Dainippon Pharma Co. Ltd. Takeda Pharmaceutical Co. Ltd. Urovant Sciences Ltd. Adrenergic receptor beta...
BioCentury | Jul 20, 2019
Emerging Company Profile

China Ophthalmology Focus eyes Asia market

Spun out from Lee’s in May and aiming for its first NDA submissions next year, China Ophthalmology Focus is already looking ahead to a Hong Kong IPO and an expansion into other Asian markets with...
BioCentury | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

Conatus cuts headcount by 40% to extend runway Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40% of its staff and suspend development of caspase 1 inhibitor CTS-2090 in a bid to extend its...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

...IgE) Chronic spontaneous urticaria Ph III Indacaterol/glycopyrronium bromide/mometasone fuorate Once-daily combination of indacaterol, a long-acting adrenergic receptor beta...
BioCentury | May 28, 2019
Distillery Therapeutics

Adrenergic receptor inhibitor combo to treat stroke

...DISEASE CATEGORY: Neurology INDICATION: Stroke Mouse studies suggest inhibiting ADRA1, ADRA2 and ADRB could help treat...
...ADRB antagonist, for arrhythmia and fibrillation. TARGET/MARKER/PATHWAY: Adrenergic receptor α1 (ADRA1); ADRA2; adrenergic receptor β (ADRB...
...same affiliaion as above email: Chris Lieu Riken Adrenergic receptor alpha 1 (ADRA1) Adrenergic receptor alpha 2 (ADRA2) Adrenergic receptor beta (ADRB) Stroke...
BioCentury | Mar 29, 2019
Clinical News

Velicept's overactive bladder therapy meets in Phase IIb

...for best-in-class efficacy and improved safety for patients with OAB." Brian Moy, Assistant Editor solabegron (GW427353) Velicept Therapeutics Inc. Adrenergic receptor beta...
BioCentury | Mar 19, 2019
Clinical News

Urovant shares slide on vibegron overactive bladder data

...receptor β 3 (ADRB3) agonists. Meghan Sullivan, Assistant Editor Beova, vibegron (KRP-114V, MK-4618, RVT-901) Roivant Sciences GmbH Urovant Sciences Ltd. Adrenergic receptor beta...
Items per page:
1 - 10 of 851